focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Regulatory News (VER)

  • There is currently no data for VER

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

29 Jun 2018 09:34

RNS Number : 0526T
Canaccord Genuity Limited
29 June 2018
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Canaccord Genuity Limited

 

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Vernalis Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Connected party to the Offeree

 

(d) Date dealing undertaken:

28 June 2018

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

No

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

Ord 1p

 

 

Purchase

Sell

5,000

50,000

 

6.30p

6.52p

 

 

6.30p

6.52p

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

NONE

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

NONE

 

Date of disclosure:

29 June 2018

Contact name:

Sam Holland

Telephone number:

020 7523 8337

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERFMGZVRLFGRZG
Date   Source Headline
8th Apr 20117:00 amRNSNotice of Results
16th Mar 20117:00 amRNSVernalis Initiates Phase I Trial of V158866
14th Mar 20117:00 amRNSAmericas Licensing Deal for tosedostat
28th Jan 20114:48 pmRNSHolding(s) in Company
21st Dec 20101:11 pmRNSHolding(s) in Company
16th Dec 20107:00 amRNSVernalis and H.Lundbeck A/S enter Collaboration
26th Nov 20104:40 pmRNSSecond Price Monitoring Extn
26th Nov 20104:35 pmRNSPrice Monitoring Extension
18th Nov 20107:00 amRNSInterim Management Statement
18th Nov 20107:00 amRNSVernalis plc: V3381 Programme Update
6th Oct 20107:00 amRNSVernalis and Servier Achieve Research Milestone
29th Jul 20107:00 amRNSInterim results for six months ended 30 June 2010
20th Jul 20104:44 pmRNSNotice of Interim Results
16th Jul 20107:00 amRNSPipeline update
29th Jun 20104:40 pmRNSSecond Price Monitoring Extn
29th Jun 20104:35 pmRNSPrice Monitoring Extension
9th Jun 20103:35 pmRNSHolding(s) in Company
7th Jun 20104:19 pmRNSHolding(s) in Company
4th Jun 20104:40 pmRNSSecond Price Monitoring Extn
4th Jun 20104:35 pmRNSPrice Monitoring Extension
3rd Jun 20103:22 pmRNSHolding(s) in Company
1st Jun 201012:32 pmRNSDirector/PDMR Shareholding
1st Jun 201012:26 pmRNSAGM Statement
19th May 20107:00 amRNSInterim Management Statement
17th May 20104:35 pmRNSPrice Monitoring Extension
4th May 20107:00 amRNSVernalis and Servier extend Oncology Collaboration
27th Apr 20105:16 pmRNSAnnual Information Update
27th Apr 20104:56 pmRNSAGM + Annual Report Notice
16th Apr 20101:17 pmRNSDirector/PDMR Shareholding
16th Apr 20101:16 pmRNSDirector/PDMR Shareholding
12th Apr 20107:00 amRNSAnnouncement of Results year ended 31 Dec 09
1st Apr 201010:30 amRNSNotice of Results
30th Mar 201012:56 pmRNSHolding(s) in Company
24th Mar 20107:00 amRNSIN-STEP Phase IIb study results
15th Mar 20107:00 amRNSVernalis earns milestone
8th Mar 20103:06 pmRNSVernalis Regains European Rights to Frovatriptan
5th Mar 20105:29 pmRNSHolding(s) in Company
5th Mar 20105:28 pmRNSHolding(s) in Company
5th Mar 20105:22 pmRNSHolding(s) in Company
2nd Mar 20105:49 pmRNSVoting Rights and Capital
1st Mar 201012:29 pmRNSResults of General Meeting
1st Mar 20107:00 amRNSPlacing & Open Offer Result
11th Feb 20104:20 pmRNSPublication of Prospectus
11th Feb 20107:00 amRNSPlacing and Open Offer
14th Dec 20097:00 amRNSVernalis announces clinical update
11th Dec 20097:00 amRNSVernalis Earns Milestone Payment
12th Nov 20097:00 amRNSInterim Management Statement
6th Oct 20094:40 pmRNSSecond Price Monitoring Extn
6th Oct 20094:35 pmRNSPrice Monitoring Extension
6th Oct 20097:00 amRNSInitiates Pilot Study of V3381 in Chronic Cough

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.